109 related articles for article (PubMed ID: 11065350)
1. Delivering erythropoietin through genetically engineered cells.
Bohl D; Heard JM
J Am Soc Nephrol; 2000 Nov; 11 Suppl 16():S159-62. PubMed ID: 11065350
[TBL] [Abstract][Full Text] [Related]
2. Improvement of mouse beta-thalassemia upon erythropoietin delivery by encapsulated myoblasts.
Dalle B; Payen E; Regulier E; Deglon N; Rouyer-Fessard P; Beuzard Y; Aebischer P
Gene Ther; 1999 Feb; 6(2):157-61. PubMed ID: 10435099
[TBL] [Abstract][Full Text] [Related]
3. Continuous delivery of human and mouse erythropoietin in mice by genetically engineered polymer encapsulated myoblasts.
Régulier E; Schneider BL; Déglon N; Beuzard Y; Aebischer P
Gene Ther; 1998 Aug; 5(8):1014-22. PubMed ID: 10326023
[TBL] [Abstract][Full Text] [Related]
4. Erythropoietin delivery by genetically engineered bone marrow stromal cells for correction of anemia in mice with chronic renal failure.
Eliopoulos N; Gagnon RF; Francois M; Galipeau J
J Am Soc Nephrol; 2006 Jun; 17(6):1576-84. PubMed ID: 16672321
[TBL] [Abstract][Full Text] [Related]
5. Myoblast transfer of human erythropoietin gene in a mouse model of renal failure.
Hamamori Y; Samal B; Tian J; Kedes L
J Clin Invest; 1995 Apr; 95(4):1808-13. PubMed ID: 7706487
[TBL] [Abstract][Full Text] [Related]
6. Successful correction of the human Cooley's anemia beta-thalassemia major phenotype using a lentiviral vector flanked by the chicken hypersensitive site 4 chromatin insulator.
Malik P; Arumugam PI; Yee JK; Puthenveetil G
Ann N Y Acad Sci; 2005; 1054():238-49. PubMed ID: 16339671
[TBL] [Abstract][Full Text] [Related]
7. Control of erythropoietin gene expression and its use in medicine.
Jelkmann W
Methods Enzymol; 2007; 435():179-97. PubMed ID: 17998055
[TBL] [Abstract][Full Text] [Related]
8. Progress toward the genetic treatment of the beta-thalassemias.
Sadelain M; Lisowski L; Samakoglu S; Rivella S; May C; Riviere I
Ann N Y Acad Sci; 2005; 1054():78-91. PubMed ID: 16339654
[TBL] [Abstract][Full Text] [Related]
9. Transfer of the feline erythropoietin gene to cats using a recombinant adeno-associated virus vector.
Beall CJ; Phipps AJ; Mathes LE; Stromberg P; Johnson PR
Gene Ther; 2000 Mar; 7(6):534-9. PubMed ID: 10757028
[TBL] [Abstract][Full Text] [Related]
10. Retrovirus-mediated transfer of the erythropoietin gene in hematopoietic cells improves the erythrocyte phenotype in murine beta-thalassemia.
Villeval JL; Rouyer-Fessard P; Blumenfeld N; Henri A; Vainchenker W; Beuzard Y
Blood; 1994 Aug; 84(3):928-33. PubMed ID: 8043875
[TBL] [Abstract][Full Text] [Related]
11. Improvement of erythropoiesis in beta-thalassemic mice by continuous erythropoietin delivery from muscle.
Bohl D; Bosch A; Cardona A; Salvetti A; Heard JM
Blood; 2000 May; 95(9):2793-8. PubMed ID: 10779423
[TBL] [Abstract][Full Text] [Related]
12. The skin as a biofactory for systemic secretion of erythropoietin: potential of genetically modified keratinocytes and fibroblasts.
Scheidemann F; Löser M; Niedermeier A; Kromminga A; Therrien JP; Vogel J; Pfützner W
Exp Dermatol; 2008 Jun; 17(6):481-8. PubMed ID: 18331333
[TBL] [Abstract][Full Text] [Related]
13. Recent advances in globin gene transfer for the treatment of beta-thalassemia and sickle cell anemia.
Sadelain M
Curr Opin Hematol; 2006 May; 13(3):142-8. PubMed ID: 16567956
[TBL] [Abstract][Full Text] [Related]
14. Modulation of erythropoietin delivery from engineered muscles in mice.
Bohl D; Heard JM
Hum Gene Ther; 1997 Jan; 8(2):195-204. PubMed ID: 9017423
[TBL] [Abstract][Full Text] [Related]
15. Optimization of human erythropoietin secretion from MLV-infected human primary fibroblasts used for encapsulated cell therapy.
Schwenter F; Déglon N; Aebischer P
J Gene Med; 2003 Mar; 5(3):246-57. PubMed ID: 12666190
[TBL] [Abstract][Full Text] [Related]
16. betaMinor-globin messenger RNA accumulation in reticulocytes governs improved erythropoiesis in beta thalassemic mice after erythropoietin complementary DNA electrotransfer in muscles.
Samakoglu S; Fattori E; Lamartina S; Toniatti C; Stockholm D; Heard JM; Bohl D
Blood; 2001 Apr; 97(8):2213-20. PubMed ID: 11290581
[TBL] [Abstract][Full Text] [Related]
17. Globin gene transfer for treatment of the beta-thalassemias and sickle cell disease.
Sadelain M; Rivella S; Lisowski L; Samakoglu S; Rivière I
Best Pract Res Clin Haematol; 2004 Sep; 17(3):517-34. PubMed ID: 15498721
[TBL] [Abstract][Full Text] [Related]
18. Correction of anemia in uremic rats by intramuscular injection of lentivirus carrying an erythropoietin gene.
Oh TK; Quan GH; Kim HY; Park F; Kim ST
Am J Nephrol; 2006; 26(4):326-34. PubMed ID: 16825758
[TBL] [Abstract][Full Text] [Related]
19. Mechanisms leading to sustained reversion of beta-thalassemia in mice by doxycycline-controlled Epo delivery from muscles.
Samakoglu S; Bohl D; Heard JM
Mol Ther; 2002 Dec; 6(6):793-803. PubMed ID: 12498775
[TBL] [Abstract][Full Text] [Related]
20. Long-term production of erythropoietin after electroporation-mediated transfer of plasmid DNA into the muscles of normal and uremic rats.
Maruyama H; Ataka K; Gejyo F; Higuchi N; Ito Y; Hirahara H; Imazeki I; Hirata M; Ichikawa F; Neichi T; Kikuchi H; Sugawa M; Miyazaki J
Gene Ther; 2001 Mar; 8(6):461-8. PubMed ID: 11313825
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
